...develop potential treatments for Parkinson's disease. The technologies are in proof-of-concept testing for the indication. MedGenesis...
...undisclosed milestones and royalties. The companies declined to disclose further terms. PharmaVentures Ltd. advised MedGenesis. MedGenesis Therapeutix Inc....

...returned $40M up front; up to $90M in milestones; 10-25% royalties; no termination fee Jan-10 MedGenesis Therapeutix Inc....

...preclinical candidate because it did not fit with the merged company's strategic and financial focus. MedGenesis...
...will receive $5 million in cash from Valeant to accelerate development of GDNF in PD. MedGenesis...
...MedGenesis has exclusive, worldwide rights to the compound from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). MedGenesis Therapeutix Inc....

...did not fit with the merged company's strategic and financial focus (see BioCentury, Oct. 4). MedGenesis...
...PD and other CNS indications (see BioCentury, Jan. 25). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. MedGenesis Therapeutix Inc....

...this year, did not fit with the merged company's strategic and financial focus. In January, MedGenesis Therapeutix Inc....

...Business: Cancer Hired: Lara Longpre as COO, formerly SVP of clinical and corporate affairs at MedGenesis Therapeutix Inc. WIR...

...Amgen granted MedGenesis exclusive, worldwide rights to glial cell-derived neurotrophic factor (GDNF) protein. Amgen received a...
...to glial cell-derived neurotrophic factor (GDNF) protein. Amgen received a high single-digit percentage stake in MedGenesis...
...undisclosed upfront payment. Amgen also is eligible for milestones and royalties. At the same time, MedGenesis...